Singapore's non-oil domestic exports to the United States rose 214.6% in October 2026 from a year earlier, the government agency Enterprise Singapore reported on 17 November 2026. It attributes the rise to pharmaceuticals, disk media products and personal computers. Across all markets the measure rose 79.8%, after 68.3% in September.1
Non-oil domestic exports, known in Singapore as NODX, leave out oil and re-exports, which the agency reports separately. The agency says its goods trade data are reported mainly in nominal terms, that is, not adjusted for price changes.1
What the release shows for the United States
The agency ranks the United States first among Singapore's ten largest markets by contribution to the change, followed by China and Taiwan. Sales to India, Indonesia and Thailand fell.1
- All non-oil domestic exports to the US: up 214.6%, after 73.2% in September.1
- Electronics to the US: up 176.6%, with disk media products up 203.3% and personal computers up 331.1%.1
- Non-electronic goods to the US: up 227.3%, after 17.4% in September.1
Singapore's Chinese-language daily Lianhe Zaobao reported the figure in the agency's terms:
对美国出口同比飙升214.6%,主要受医药产品、磁盘媒体产品(+203.3%)和个人电脑(+331.1%)出口带动。
Exports to the United States soared 214.6% year on year, driven mainly by pharmaceuticals, disk media products (+203.3%) and personal computers (+331.1%).2
The release gives no growth rate for medicines sold to the United States and no explanation for the rise. For all markets together it puts pharmaceutical exports up 253.1%, an increase of S$2.3 billion. It says electronics were supported by demand related to artificial intelligence. It does not mention tariffs.1
The rise is measured against a month in which those exports had fallen. In October 2025 the same agency reported that non-oil domestic exports to the United States had fallen 12.5% from a year earlier, and non-electronic goods to the US 22.8%.3
The largest single contribution to October's rise across all markets is one the release does not tie to any market. Structures of ships and boats added S$4.8 billion, and the agency declines to state a growth rate for them because, in its words, "the exceptionally high percentage growth reflects a low base effect in the same period last year". It calls those exports lumpy.1
Which US tariffs apply to Singapore
Singapore has a free-trade agreement with the United States, but that does not exempt its goods from the tariff Washington introduced in July 2026. Enterprise Singapore's guidance to exporters, marked as updated on 24 September 2026, says Singapore is one of 60 economies on which the US Trade Representative imposed a tariff under Section 301 of the Trade Act of 1974, the law that allows tariffs after an investigation of a foreign practice. The stated ground is a failure to impose or effectively enforce a ban on imports made with forced labour. The rate for Singapore is 12.5% and took effect on 24 July 2026, when a temporary 10% surcharge on all imports expired. The guidance says the tariff applies on top of ordinary duties and that goods qualifying under the free-trade agreement still pay it.4
The US Trade Representative's announcement of 23 July 2026 sets 10% for 17 economies that have such a ban, have committed to one or have a partial regime, 10% or 12.5% net of the ordinary duty for certain products of the European Union, Taiwan, Japan, South Korea and Switzerland, and 12.5% for all other investigated economies. It describes categories of exempt products without listing them one by one.5
The product the agency names first for the United States is, by its own guidance, outside that tariff. The guidance gives pharmaceuticals and pharmaceutical ingredients as examples of exempt goods, along with certain aerospace products and certain semiconductor manufacturing equipment. Whether disk media products and personal computers are also exempt is not stated in the pages read for this article.4
Medicines are covered instead by a separate US measure under Section 232, the law on imports judged to threaten national security. Proclamation 11020 sets a 100% duty on patented pharmaceuticals, applied from 31 July 2026 to companies it names and from 29 September 2026 to others. It sets 15% for products of Japan, the European Union, South Korea, and Switzerland and Liechtenstein, 20% for companies with approved plans to move production to the United States, and zero for companies that also have a pricing agreement with the US government. Generic medicines are not covered at this time.6
The proclamation does not mention Singapore. The proclamation names no rate for Singapore, and Enterprise Singapore's guidance lists 100% for patented medicines, with 20% or zero for companies holding the agreements described above. A patented medicine made in Singapore therefore pays 100% unless its manufacturer qualifies for a company rate. The trade figures do not show which companies shipped the medicines in October or what duty, if any, they paid.1 6
What is not known
Enterprise Singapore's release contains no forecast and no comment on whether October's level will last. The monthly figures move sharply: non-electronic exports to the United States rose 17.4% in September and 227.3% in October. Over the first ten months of 2026 non-oil domestic exports to all markets grew 33.6%, well below October's rate.1
Enterprise Singapore publishes these figures monthly. The October data came out on 17 November 2026 and the October 2025 data on 17 November 2025. The next release, for November, should give the growth rate of exports to the United States; the October release gave no separate figure for medicines sold there.1 3